Chiara Corti

Dr. Chiara Corti

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2020 in Genes
Verified
Journal Article
Open access
PDF file
Nicola FuscoNicola Fusco
Nicola Fusco
Elham SajjadiElham Sajjadi
Elham Sajjadi
Konstantinos VenetisKonstantinos Venetis
Konstantinos Venetis
GGGabriella Gaudioso
Gabriella Gaudioso
GLGianluca Lopez
Gianluca Lopez
Marco InvernizziMarco Invernizzi
Marco Invernizzi
Alterations in the tumor suppressor phosphatase and tensin homolog (PTEN) occur in a substantial proportion of solid tumors. These events drive tumorigenesis and tumor progression. Given its central role as a downregulator of the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, PTEN is deeply involved in cell growth, proliferation, and survival. This gene is also implicated in the modulation of the DNA damage response and in tumor immune microenvironment modeling. Despite the actionability of PTEN alterations, their role as biomarkers remains controversial in clinical practice. To date, there is still a substantial lack of validated guidelines and/or recommendations for PTEN testing. Here, we provide an update on the current state of knowledge on biologic and genetic alterations of PTEN across the most frequent solid tumors, as well as on their actual and/or possible clinical applications. We focus on possible tailored schemes for cancer patients’ clinical management, including risk assessment, diagnosis, prognostication, and treatment.

18 February 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
PTPaolo Tarantino
Paolo Tarantino
CCChiara Corti
Chiara Corti
PSPeter Schmid
Peter Schmid
Javier CortesJavier Cortes
Javier Cortes
EMElizabeth A. Mittendorf
Elizabeth A. Mittendorf
GCGiuseppe Curigliano
Giuseppe Curigliano
For decades, the systemic treatment of localized triple negative breast cancer (TNBC) has exclusively relied on chemotherapy. Recent advancements, however, are rapidly reshaping the treatment algorithms for this disease. The addition of pembrolizumab to neoadjuvant chemotherapy has indeed shown to significantly improve event-free survival for stage II–III TNBC, leading to its establishment as new standard of care in this setting. This landmark advancement has however raised several important scientific questions. Indeed, we desperately need strategies to identify upfront patients deriving benefit from the addition of immunotherapy. Moreover, the best integration of pembrolizumab with further recent advancements (capecitabine, olaparib) is yet to be defined. Lastly, extensive efforts are needed to minimize the impact on patients of immune-related adverse events and financial toxicity. The next decade of clinical research will be key to overcome these challenges, and ultimately learn how to optimally integrate immunotherapy in the treatment landscape of TNBC.

11 December 2022 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
CCChiara Corti
Chiara Corti
MCMarisa Cobanaj
Marisa Cobanaj
EDEdward C. Dee
Edward C. Dee
CCCarmen Criscitiello
Carmen Criscitiello
STSara M. Tolaney
Sara M. Tolaney
GCGiuseppe Curigliano
Giuseppe Curigliano

1 February 2022 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
CCChiara Corti
Chiara Corti
GAGabriele Antonarelli
Gabriele Antonarelli
CCCarmen Criscitiello
Carmen Criscitiello
NLNancy U. Lin
Nancy U. Lin
LCLisa A. Carey
Lisa A. Carey
GCGiuseppe Curigliano
Giuseppe Curigliano

22 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
CCChiara Corti
Chiara Corti
PGPier P.M.B. Giachetti
Pier P.M.B. Giachetti
AEAlexander M.M. Eggermont
Alexander M.M. Eggermont
SDSuzette Delaloge
Suzette Delaloge
GCGiuseppe Curigliano
Giuseppe Curigliano

24 March 2022 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
CCChiara Corti
Chiara Corti
Konstantinos VenetisKonstantinos Venetis
Konstantinos Venetis
Elham SajjadiElham Sajjadi
Elham Sajjadi
LZLorenzo Zattoni
Lorenzo Zattoni
GCGiuseppe Curigliano
Giuseppe Curigliano
Nicola FuscoNicola Fusco
Nicola Fusco
. Most breast cancer-related deaths arise from triple-negative breast cancer (TNBC). Molecular heterogeneity, aggressiveness and the lack of effective therapies are major hurdles to therapeutic pro...